SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-007047
Filing Date
2024-05-07
Accepted
2024-05-07 16:10:17
Documents
15
Period of Report
2024-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ymab-20240507x8k.htm   iXBRL 8-K 35723
2 EX-99.1 ymab-20240507xex99d1.htm EX-99.1 207255
3 GRAPHIC ymab-20240507xex99d1001.jpg GRAPHIC 5043
  Complete submission text file 0001558370-24-007047.txt   387589

Data Files

Seq Description Document Type Size
4 EX-101.SCH ymab-20240507.xsd EX-101.SCH 3397
5 EX-101.LAB ymab-20240507_lab.xml EX-101.LAB 15924
6 EX-101.PRE ymab-20240507_pre.xml EX-101.PRE 10316
18 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20240507x8k_htm.xml XML 4797
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

IRS No.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 24921921
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)